Becker Muscular Dystrophy Treatment Market to Witness Growth by 2030 | Key Companies – PTC Therapeutics, Italfarmaco, Epirium Bio, Edgewise Therapeutics, and Several Others

October 27 02:56 2021
Becker Muscular Dystrophy Treatment Market to Witness Growth by 2030 | Key Companies - PTC Therapeutics, Italfarmaco, Epirium Bio, Edgewise Therapeutics, and Several Others
Delveinsight Business Research LLP
DelveInsight’s “Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Becker Muscular Dystrophy Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Becker Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030.

It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Becker Muscular Dystrophy Market

Becker Muscular Dystrophy: An Overview

Becker Muscular Dystrophy (BMD) is an inherited muscle structure disorder that results in progressive deterioration of limbs, cardiac and skeletal muscles. However, the involuntary muscles are not affected. BMD is a milder version of Duchenne Muscular Dystrophy (DMD). BMD usually begins in the teens or early adulthood, and the course is slower and far less predictable than that of DMD.

Becker Muscular Dystrophy Market Key Facts

  • According to the American Association of Neuromuscular & Electrodiagnostic Medicine, approximately three out of every 100,000 people gets affected by BMD. Additionally, few BMD patients can live a normal lifespan, however, most die sometime after the age of 40.

  • Through several studies, it can be estimated that the occurrence of BMD varies from one per 18,000 to one per 31,000 male births. 
  • According to the Genetic and Rare Diseases Information Center, the prevalence of BMD is estimated to be between 17–27 cases per million people. This means that at a given time, about one in 37,000 to one in 59,000 people are living with BMD.

  • As per the CDC, the estimated prevalence of Duchenne and Becker muscular dystrophy (DBMD) was one in every 7,250 males aged 5–24 years. However, the prevalence of DMD was found to be three times higher than the prevalence of BMD. 

Get FREE sample copy at Becker Muscular Dystrophy Therapeutics Market

Key Benefits of Becker Muscular Dystrophy Market Report

  • The report provides an in-depth analysis of Becker Muscular Dystrophy Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Becker Muscular Dystrophy Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Becker Muscular Dystrophy current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Becker Muscular Dystrophy market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Becker Muscular Dystrophy Market 

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Becker Muscular Dystrophy market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Becker Muscular Dystrophy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Becker Muscular Dystrophy Epidemiology

The epidemiology section covers insights about the historical and current Becker Muscular Dystrophy patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Becker Muscular Dystrophy (BMD) Epidemiology Segmentation

  • Prevalent Cases of BMD

  • Age-specific Prevalent Cases

  • Diagnosed and Treatable Cases

Becker Muscular Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Becker Muscular Dystrophy market or expected to get launched in the market during the study period. The analysis covers Becker Muscular Dystrophy market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Becker Muscular Dystrophy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

The treatment of Becker Muscular Dystrophy focuses on lessening the symptoms associated with it. There is no cure, but treatments are available to help with symptoms and maximize muscle function. It is vital that a person with BMD stay in shape and continue to use their muscles. 

To bridge the gap in the treatment landscape, globally several companies are actively working to develop therapies for Becker Muscular Dystrophy (BMD).

Key players in the Becker Muscular Dystrophy (BMD) Market include:

  • PTC Therapeutics

  • Italfarmaco

  • Epirium Bio

  • Edgewise Therapeutics

And others

Becker Muscular Dystrophy (BMD) Therapies covered in the report includes:

  • Translarna

  • Givinostat

  • EPM-01

  • EDG-5506

And many others. 

As per the DelveInsight, the dynamics of the Becker Muscular Dystrophy (BMD) market is anticipated to change in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage by key players. The launch of emerging therapies is expected during the forecast period of 2021–2030.

Request for Sample @ Becker Muscular Dystrophy Emerging Therapies and Key Companies

Table of Content

1. Key Insights

2. Executive Summary 

3. Becker Muscular Dystrophy Competitive Intelligence Analysis

4. Becker Muscular Dystrophy Market Overview at a Glance

5. Becker Muscular Dystrophy Disease Background and Overview

6. Becker Muscular Dystrophy Patient Journey

7. Becker Muscular Dystrophy Epidemiology and Patient Population

8. Becker Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Becker Muscular Dystrophy Unmet Needs

10. Key Endpoints of Becker Muscular Dystrophy Treatment

11. Becker Muscular Dystrophy Marketed Products

12. Becker Muscular Dystrophy Emerging Therapies

13. Becker Muscular Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Becker Muscular Dystrophy Market Outlook (7 major markets)

16. Becker Muscular Dystrophy Access and Reimbursement Overview

17. KOL Views on the Becker Muscular Dystrophy Market.

18. Becker Muscular Dystrophy Market Drivers

19. Becker Muscular Dystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Key Companies and the Emerging Gene Therapy in the Dermatology

Globally, several prominent pharmaceutical companies are exploring the potential application of gene therapy in dermatology including Krystal Biotech, Castle Creek Biosciences, Biosciences, Almirall, Abeona Therapeutics, Fibrocell Science, Amryt Pharma plc, Sterna Biologicals GmbH & Co. KG, Temprian Therapeutics, Holostem Terapie Avanzate, Azitra, Novartis, AVITA Medical, and others. Looking at the market prospects and positive outcomes, new players are also expected to enter the domain in the coming years, making it one of the most competitive gene therapy segments. Read More: Leading Gene Therapy Companies in Dermatology

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States